HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.

Abstract
Immunoglobulin G (IgG) antibodies to Epstein-Barr virus (EBV) nuclear antigens 2 and 1 (EBNA-2 and EBNA-1, respectively) were studied using sera from healthy individuals of a population with a high incidence of asymptomatic primary EBV infections during infancy or childhood in Japan. Two CHO-K1 cell lines expressing EBNA-2 and EBNA-1 were used for anticomplement and indirect immunofluorescence assays. The positivity rate for EBNA-2 IgG rose in the 1- to 2-year age group, increased and remained at a plateau ( approximately 45%) between 3 and 29 years of age (3- to 4-, 5- to 9-, 10- to 14-, and 15- to 29-year age groups), and then reached 98% by age 40 (>/== 40-year age group). Both seropositivity for EBNA-1 and seropositivity for EBNAs in Raji cells (EBNA/Raji) were detected in the 1- to 2-year age group, remained high, and finally reached 100% by age 40. The geometric mean titer (GMT) of EBNA-2 IgG reached a plateau in the 5- to 9- and 10- to 14-year-old groups and remained elevated in the older age groups (15 to 29 and >/== 40 years). The GMT of EBNA-1 IgGs increased to a plateau in the 1- to 2-year-old group and remained unchanged in the older age groups. The GMT of EBNA/Raji IgGs also reached a plateau in the 1- to 2-year-old group, remained level throughout the 3- to 14-year age groups, and decreased in the 15- to 29-year-olds. EBNA-2 IgGs emerged earlier than EBNA-1 IgGs in 8 of 10 patients with infectious mononucleosis, who were between 1 and 27 years old, and declined with time in three of eight cases. These results suggest that EBNA-2 IgG antibodies evoked in young children by asymptomatic primary EBV infections remain elevated throughout life, probably because of reactivation of latent and/or exogenous EBV superinfection.
AuthorsShizuko Harada, Yoshio Kamata, Yasuyuki Ishii, Hiroyuki Eda, Ryo Kitamura, Maya Obayashi, Sayuri Ito, Fumihiko Ban, Jun Kuranari, Haruhiko Nakajima, Tomoko Kuze, Masao Hayashi, Nobuhiko Okabe, Hidenobu Senpuku, Nobuyuki Miyasaka, Yoshiko Nakamura, Hirokazu Kanegane, Kazuo Yanagi
JournalClinical and diagnostic laboratory immunology (Clin Diagn Lab Immunol) Vol. 11 Issue 1 Pg. 123-30 (Jan 2004) ISSN: 1071-412X [Print] United States
PMID14715558 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Viral
  • Complement Inactivator Proteins
  • EBNA-2 protein, Human herpesvirus 4
  • Epstein-Barr Virus Nuclear Antigens
  • Immunoglobulin G
  • Viral Proteins
  • anticomplement
  • EBV-encoded nuclear antigen 1
Topics
  • Adolescent
  • Adult
  • Animals
  • Antibodies, Viral (blood)
  • CHO Cells
  • Child
  • Child, Preschool
  • Complement Inactivator Proteins (analysis)
  • Cricetinae
  • Epstein-Barr Virus Infections (epidemiology, immunology)
  • Epstein-Barr Virus Nuclear Antigens (immunology)
  • Fluorescent Antibody Technique, Indirect
  • Herpesvirus 4, Human (immunology)
  • Humans
  • Immunoglobulin G (blood)
  • Infant
  • Japan (epidemiology)
  • Viral Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: